Last reviewed · How we verify
sodium selenite pentahydrate
sodium selenite pentahydrate is a Antioxidant Small molecule drug developed by Seoul National University Hospital. It is currently in Phase 3 development for Acute promyelocytic leukemia. Also known as: Selentab inj. A12CE02.
Sodium selenite pentahydrate is a selenium compound that acts as an antioxidant and has been investigated for its potential to reduce oxidative stress and inflammation.
Sodium selenite pentahydrate is a selenium compound that acts as an antioxidant and has been investigated for its potential to reduce oxidative stress and inflammation. Used for Acute promyelocytic leukemia.
At a glance
| Generic name | sodium selenite pentahydrate |
|---|---|
| Also known as | Selentab inj. A12CE02 |
| Sponsor | Seoul National University Hospital |
| Drug class | Antioxidant |
| Modality | Small molecule |
| Therapeutic area | Oxidative stress and inflammation-related diseases |
| Phase | Phase 3 |
Mechanism of action
Sodium selenite pentahydrate works by donating electrons to reactive oxygen species, thereby neutralizing their harmful effects. This can help to reduce inflammation and oxidative stress, which are associated with various diseases. However, the exact mechanisms of its therapeutic effects are not fully understood.
Approved indications
- Acute promyelocytic leukemia
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (PHASE3)
- Selenium for Musculoskeletal Health (PHASE3)
- Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone (PHASE1)
- Selenium to Improve Neurological Outcome After Cardiac Arrest (PHASE2)
- Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sodium selenite pentahydrate CI brief — competitive landscape report
- sodium selenite pentahydrate updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about sodium selenite pentahydrate
What is sodium selenite pentahydrate?
How does sodium selenite pentahydrate work?
What is sodium selenite pentahydrate used for?
Who makes sodium selenite pentahydrate?
Is sodium selenite pentahydrate also known as anything else?
What drug class is sodium selenite pentahydrate in?
What development phase is sodium selenite pentahydrate in?
What are the side effects of sodium selenite pentahydrate?
Related
- Drug class: All Antioxidant drugs
- Manufacturer: Seoul National University Hospital — full pipeline
- Therapeutic area: All drugs in Oxidative stress and inflammation-related diseases
- Indication: Drugs for Acute promyelocytic leukemia
- Also known as: Selentab inj. A12CE02
- Compare: sodium selenite pentahydrate vs similar drugs
- Pricing: sodium selenite pentahydrate cost, discount & access